1.Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis.
Xiao-Ming DU ; Liu-Hua WANG ; Xiao-Wen CHEN ; Yi-Xiao LI ; Yu-Cong LI ; Yu-Wen CAO
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(3):305-312
The aim of the present study was to accurately evaluate the association of Sox2 expression with the survival of patients with digestive tract cancers. Relevant literatures were identified by comprehensively searching databases including the Pubmed, Embase, CBMdisc, and Wanfang (up to October 2014). A meta-analysis was performed to clarify the association between Sox2 expression and overall survival or clinicopathological parameters of patients with digestive tract cancers (esophageal, gastric, and colorectal cancers). The results showed a significant association between high Sox2 expression and poor overall survival in patients with digestive tract carcinomas (HR=1.55, 95% CI=1.04-2.31), especially for patients with esophageal cancer (HR=2.04, 95%CI=1.30-3.22), colorectal cancer (HR=1.40, 95% CI=1.04-1.89), and digestive tract adenocarcinoma (HR=1.80, 95% CI=1.12-2.89), for Europeans (HR=1.98, 95% CI=1.44-2.71) or patients who did not receive neoadjuvant treatment (HR=1.73, 95% CI=1.10-2.72). Furthermore, Sox2 over-expression was highly correlated with vascular invasion (OR=1.86, 95% CI=1.25-2.77) and poor differentiation (OR=1.88, 95% CI=1.14-3.08), especially in esophageal and colorectal cancers. In conclusion, Sox2 expression may serve as a novel prognostic factor for patients with digestive tract cancers. Over-expression of Sox2 that is correlated with vascular invasion and poor differentiation suggests poor outcomes of patients with digestive tract cancers.
Antineoplastic Agents
;
therapeutic use
;
Biomarkers, Tumor
;
genetics
;
metabolism
;
Colorectal Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Esophageal Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Gastrointestinal Tract
;
metabolism
;
pathology
;
Gene Expression
;
Humans
;
Neoadjuvant Therapy
;
methods
;
Neoplasm Grading
;
Neoplasms, Vascular Tissue
;
diagnosis
;
drug therapy
;
mortality
;
secondary
;
Prognosis
;
SOXB1 Transcription Factors
;
genetics
;
metabolism
;
Stomach Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Survival Analysis
2.Clinical Significance of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphism in Korean Patients with Gastric Cancer.
Jun LEE ; Cheol Kweon JEONG ; Sung Pyo HONG ; So Young CHONG ; Doyeun OH ; Seong Gyu HWANG ; Dae Ho AHN ; Sehyun KIM ; Jin Hee HAN ; Nam Keun KIM
The Korean Journal of Gastroenterology 2005;46(1):32-38
BACKGROUND/AIMS: Thymidylate synthase (TS) is a target enzyme of 5-fluorouracil (5-FU) and has a polymorphic 28 bp tandem repeated sequence. TS enhancer region (TSER) polymorphism has been associated with the efficacy of 5-FU-based chemotherapy in colon cancer. Methylenetetrahydrofolate reductase (MTHFR) plays a central role in converting folate to methyl donor for DNA methylation. The aim of this study was to determine the clinical value of TSER and MTHFR polymorphism in gastric cancer. METHODS: From October, 1995 to February, 2002, 40 gastric cancer patients underwent operation and 25 patients among those patients have received postoperative 5-FU-based chemotherapy (5-FU (+) group). Peripherial blood were sampled for TSER and MTHFR genotype analysis by PCR amplification of genomic DNA. The survival of patients according to TSER and MTHFR polymorphism were compared. RESULTS: We observed a longer survival in stage II than stage III of the patients (p=0.0037). However, the TSER and MTHFR C677T polymorphisms were not associated with better survival of gastric cancer patients as well as combined TSER and MTHFR genotypes with 5-FU chemotherapy. CONCLUSIONS: The TSER and MTHFR genotypes are not effective markers for tumor sensitivity to 5-FU-based chemotherapy in Korean gastric cancer patients after curative resection. These results may suggest further large-scale study about TSER and MTHFR polymorphism for the prediction of efficacy of 5-FU-based chemotherapy in gastric cancer in Korea.
Aged
;
Antimetabolites, Antineoplastic/*therapeutic use
;
Drug Screening Assays, Antitumor
;
Female
;
Fluorouracil/*therapeutic use
;
Humans
;
Male
;
Methylenetetrahydrofolate Reductase (NADPH2)/*genetics
;
Middle Aged
;
*Polymorphism, Genetic
;
Stomach Neoplasms/*drug therapy/genetics/mortality
;
Survival Rate
;
Thymidylate Synthase/*genetics